- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06236425
TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
March 6, 2024 updated by: H. Lee Moffitt Cancer Center and Research Institute
A Phase IB Clinical Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes [TIL]) and Pembrolizumab With or Without Chemotherapy in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Phase 1b open-label study to evaluate the safety of selected TIL (TBio-4101) delivered after lymphodepleting chemotherapy and followed by intravenous (IV) bolus aldesleukin (IL-2) and pembrolizumab for patients with advanced HNSCC who have initially progressed on pembrolizumab or pembrolizumab/platinum chemotherapy.
Study Overview
Status
Recruiting
Study Type
Interventional
Enrollment (Estimated)
15
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Tina Swartzlander
- Phone Number: 813-745-5517
- Email: Tina.Swartzlander@moffitt.org
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- Recruiting
- Moffitt Cancer Center
-
Sub-Investigator:
- Christine Chung, MD
-
Principal Investigator:
- Kedar Kirtane, MD
-
Contact:
- Tina Swartzlander
- Phone Number: 813-745-5517
- Email: Tina.Swartzlander@moffitt.org
-
Sub-Investigator:
- Guilherme Rabinowits, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients must have pathologically confirmed, recurrent, unresectable or metastatic solid tumors of HNSCC, excluding nasopharyngeal and nasal cavity carcinomas, and must have received no prior treatment for metastatic disease.
- Patients must have at least 1 cm3 (1.1 g) of viable tumor tissue amenable for resection for TIL generation, and at least one target tumor that can be used for response assessment by RECIST 1.1 and iRECIST criteria and for mandatory translational tumor biopsy (where applicable).
- Patients must be willing and able to undergo an apheresis procedure.
- Any systemic therapy, including anti-cancer monoclonal antibodies, must have been completed at least 3 weeks prior to TIL harvest or apheresis, whichever is earlier, and any prior therapy-related adverse events (AEs) must have resolved to Grade ≤ 1 except for alopecia and vitiligo. Neuropathy and anemia must have resolved to Grade ≤ 2.
- Age 18-75 years at the time of TIL harvest.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Participants given pembrolizumab monotherapy must have a composite positive score ≥ 1.
- Demonstrate adequate organ and marrow function.
- Seronegative for Human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen, and hepatitis C (HCV) antibody (if HCV antibody positive, must be tested for HCV RNA, which must be negative to be eligible).
- The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.
- The effects of TBio-4101 on the developing human fetus are unknown. For this reason and because other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of study drug administration.
Exclusion Criteria:
- Participants with a known additional malignancy that is progressing or has required active treatment within the past 3 years.
- Participants who have received prior cell therapy or prior organ transplant.
- Participants who have received any previous treatment with a PD-1 or PD-L1 inhibitor, including but not limited to: nivolumab, atezolizumab, pembrolizumab, avelumab, or durvalumab.
- Participants who are receiving any other investigational agents.
- Participants who have a history of severe immediate hypersensitivity reaction to the study agents or any of their constituents.
- Participants who have a severe allergy to gentamicin (used in the manufacturing of TBio-4101).
- Participants who have received a live or live-attenuated vaccine within 30 days prior to TIL harvest or apheresis, whichever is earlier. Note: Administration of killed vaccines is allowed.
- Participants who require chronic anti-coagulant therapy that cannot either be discontinued or changed to an anti-coagulant with a relatively short half-life, such as a low molecular weight heparin.
- Participants with either a primary immunodeficiency disorder (i.e., severe combined immunodeficiency syndrome) or acquired immunodeficiency disorders (such as HIV/AIDS).
- Participants with a diagnosis of immunodeficiency or receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to TIL harvest or apheresis, whichever is earlier.
- Participants with a serious cardiac condition, such as uncontrolled hypertension, concurrent congestive heart failure, prior history of Class III/IV cardiac disease (New York Heart Association [NYHA]), left ventricular ejection fraction (LVEF) <45% at baseline, history of cardiac ischemia within the past 6 months, or prior history of cardiac arrhythmia requiring treatment, unless approved by the Sponsor (MCC). Participants who are > 60 years of age must undergo cardiology clearance exam and cardiac stress test, unless performed within the last 6 months and there has been no clinical change with respect to heart function.
- Participants with a forced expiratory volume (FEV1) ≤ 60% of predicted value and diffusing capacity of the lung for carbon monoxide (DLCO) (corrected) < 60% of predicted value.
- Participants with known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to TIL harvest/ apheresis.
- Participants with active infections requiring parenteral antibiotics that, in the opinion of the Investigator, would increase the risk of adverse events during TIL harvest or apheresis or start of NMA-LD chemotherapy.
- Participants with a history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the patient to participate, in the opinion of the treating Investigator.
- Pregnant women are excluded from this study because the effects of TBio-4101 on the developing human fetus are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with TBio-4101, breastfeeding should be discontinued.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: TIL Harvest/Standard of care Treatment Phase
Participants will undergo tumor harvest for TIL and then receive 2 to 3 cycles of pembrolizumab or pembrolizumab/platinum chemotherapy (cisplatin or carboplatin / 5-FU) as per standard of care.
|
Will be administered as per standard of care.
Participants with initial partial or complete radiographic response will continue on the same therapy at the discretion of the treating physician.
Other Names:
Will be administered as per standard of care.
Participants with initial partial or complete radiographic response will continue on the same therapy at the discretion of the treating physician.
Other Names:
|
Experimental: TBio-4101 Treatment
Participants without radiographic response (progressive disease) after pembrolizumab or pembrolizumab/platinum chemotherapy, and who meet eligibility requirements, will transition to receive TBio-4101.
Participants will receive TBio-4101 infusion and after completion of TBio-4101 infusion, IL-2 will be administered every 8 hours, for up to 6 doses.
Finally, pembrolizumab will be administered on Day 14, Day 35, and Day 56 and Q6W (beginning Week 12) thereafter for up to 2 years until discontinuation.
|
TBio-4101 is a tumor-infiltrating lymphocyte (TIL) product that involves the use of special immune cells called T-cells.
A T-cell is a type of lymphocyte, or white blood cell.
Other Names:
Will be administered as per standard of care.
Participants with initial partial or complete radiographic response will continue on the same therapy at the discretion of the treating physician.
Other Names:
Will be administered as per standard of care.
Participants with initial partial or complete radiographic response will continue on the same therapy at the discretion of the treating physician.
Other Names:
Participants who proceed to TBio-4101 treatment will receive Cyclophosphamide as part of a non-myeloablative lymphodepletion (NMA-LD) chemotherapy regimen prior to TBio-4101 infusion.
Other Names:
Participants who proceed to TBio-4101 treatment will receive Fludarabine as part of a non-myeloablative lymphodepletion (NMA-LD) chemotherapy regimen prior to TBio-4101 infusion.
Other Names:
After completion of TBio-4101 infusion, Aldesleukin will be administered every 8 hours, for up to 6 doses.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability
Time Frame: Up to 2 years
|
The incidence of treatment-emergent adverse events will be tabulated using NCI CTCAE v5.0
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR)
Time Frame: Up to 5 years
|
ORR will be determined using RECIST 1.1 and RECIST 1.1 for immune-based therapeutics (iRECIST).
|
Up to 5 years
|
Durable Response Rate (DRR)
Time Frame: Up to 5 years
|
DRR, will be defined as a continuous CR or partial response (PR) beginning within 12 months of TBio-4101 treatment and lasting ≥ 6 months by RECIST 1.1 and iRECIST.
|
Up to 5 years
|
Duration of Response (DoR)
Time Frame: Up to 5 years
|
DoR will be determined using RECIST 1.1 and iRECIST.
|
Up to 5 years
|
Disease Control Rate (DCR)
Time Frame: Up to 5 years
|
DCR will be determined using RECIST 1.1 and iRECIST.
|
Up to 5 years
|
Assess the feasibility of TBio-4101
Time Frame: Up to 5 years
|
Feasibility of TBio-4101 defined as the percentage of treated-patient population (TPP) patients over intent-to-treat (ITT).
|
Up to 5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Kedar Kirtane, MD, Moffitt Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 5, 2024
Primary Completion (Estimated)
May 1, 2026
Study Completion (Estimated)
May 1, 2026
Study Registration Dates
First Submitted
January 24, 2024
First Submitted That Met QC Criteria
January 24, 2024
First Posted (Actual)
February 1, 2024
Study Record Updates
Last Update Posted (Actual)
March 7, 2024
Last Update Submitted That Met QC Criteria
March 6, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Head and Neck Neoplasms
- Neoplasms, Squamous Cell
- Carcinoma
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Antiviral Agents
- Anti-HIV Agents
- Anti-Retroviral Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Aldesleukin
- Cyclophosphamide
- Carboplatin
- Cisplatin
- Pembrolizumab
- Fludarabine
- Interleukin-2
Other Study ID Numbers
- MCC-23098
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Squamous Cell Carcinoma of Head and Neck
-
Washington University School of MedicineMerck Sharp & Dohme LLCActive, not recruitingHead and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Carcinoma, Squamous Cell of Head and Neck | Neoplasms, Head and Neck | Squamous Cell Carcinoma, Head and NeckUnited States
-
Bristol-Myers SquibbActive, not recruitingSquamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and NeckFrance
-
Washington University School of MedicineCelgene CorporationActive, not recruitingHead and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and Neck | Carcinoma, Squamous Cell of the Head and NeckUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingRecurrent Head and Neck Squamous Cell Carcinoma | Advanced Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma | Locally Advanced Head and Neck Squamous Cell Carcinoma | Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage IV Cutaneous...United States
-
University of PittsburghNational Cancer Institute (NCI)TerminatedSquamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma, Head And Neck | Carcinoma, Squamous Cell of Head and NeckUnited States
-
National Cancer Institute (NCI)Not yet recruitingStage II Squamous Cell Carcinoma of the Head and Neck | Stage III Squamous Cell Carcinoma of the Head and Neck | Stage IV Squamous Cell Carcinoma of the Head and NeckUnited States
-
Eben RosenthalNational Cancer Institute (NCI)CompletedHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN)United States
-
Case Comprehensive Cancer CenterNot yet recruitingHead and Neck Squamous Cell Carcinoma | Recurrent Squamous Cell Carcinoma of the Head and Neck | Metastatic Squamous Cell CarcinomaUnited States
-
Washington University School of MedicineActive, not recruitingSquamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma, Head and NeckUnited States
-
Arnaud Bewley, MDNational Cancer Institute (NCI); Genentech, Inc.TerminatedStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck | Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and NeckUnited States
Clinical Trials on TBio-4101
-
Forma Therapeutics, Inc.ProSciento, Inc.TerminatedNonalcoholic Steatohepatitis (NASH) | Overweight or ObesityUnited States
-
Turnstone Biologics, Corp.RecruitingBreast Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Uveal Melanoma | Cutaneous MelanomaUnited States, Canada
-
Axonics, Inc.RecruitingUrinary Urge Incontinence (UUI) | Fecal Incontinence (FI) | Urinary Frequency (UF)Netherlands, United States
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RecruitingMetastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous MelanomaUnited States
-
Turnstone Biologics, Corp.TakedaTerminatedRenal Cell Carcinoma | Cervical Cancer | Solid Tumor | Mesothelioma | Melanoma (Skin) | Oropharynx Cancer | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Microsatellite Stable Colorectal Cancer | Cutaneous Squamous Cell CarcinomaUnited States, Canada, Korea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedHealthyKorea, Republic of